Press Release: Epizyme : Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has
Read full article »
Epizyme is a Massachusetts-based biopharmaceutical company that develops and commercializes novel epigenetic medicines for the treatment of cancer.
Read more